Last reviewed · How we verify

Bioroma — Portfolio Competitive Intelligence Brief

Bioroma pipeline: 5 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Triptorelin plus daily FSH anh LH Triptorelin plus daily FSH anh LH marketed
Triptorelin and recombinant FSH Triptorelin and recombinant FSH marketed
Daily FSH and GnRH antagonist Daily FSH and GnRH antagonist marketed
Daily FSH and LH plus Cetrorelix Daily FSH and LH plus Cetrorelix marketed
Long acting FSH and GnRH antagonist Long acting FSH and GnRH antagonist marketed GnRH antagonist / FSH receptor agonist combination GnRH receptor, FSH receptor Reproductive Endocrinology / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Bioroma:

Cite this brief

Drug Landscape (2026). Bioroma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioroma. Accessed 2026-05-14.

Related